U(

United States Drug Testing Laboratories (Usdtl)

www.usdtl.com link_icon

Company-Focused Market Research Report: United States Drug Testing Laboratories, Inc. (USDTL)



Company Overview



  • Name: United States Drug Testing Laboratories, Inc. (USDTL)

  • Mission: To ensure the hardest cases do not go without resolution by specializing in niche areas of forensic drug and alcohol testing, using the best science available to provide cutting-edge tools for analysis and evaluation of exposure to alcohol, substances of abuse, and toxins.

  • Founded: No information is available

  • Founders: No information is available

  • Key People:

  • Veronica N. Lewis: Chief Executive Officer, MS, MT(ASCP)SBB

  • Douglas Lewis: Founder, President, and Scientific Director, D.Sc.

  • Joseph Jones: Chief Operating Officer and Executive Vice President, Ph.D., NRCC-TC

  • James R. Lesch: Chief Financial Officer, MBA, CPA

  • Donna Coy: Laboratory Director, Ph.D., NRCC-TC

  • Priti Soni: Director of IT, MIS

  • Michelle Lach: Director of Communications, MSIMC

  • Headquarters: No specific information is available

  • Number of Employees: No information is available

  • Revenue: No information is available

  • Known For: Leading in toxicology, alcohol biomarkers, and substance use testing for all stages of life with a focus on innovative and rigorous analytical toxicology research and comprehensive specimen testing.


Products



USDTL is known for advanced toxicological testing services, specializing in drug and alcohol detection. They offer a range of specific testing solutions:

1. Newborn Testing
  • Umbilical Cord Tissue Testing: Detects prenatal exposure to alcohol and drugs.

  • Meconium Testing: Offers evaluation of drugs and alcohol exposure in newborns.


2. Adult & Child Testing
  • Fingernail Testing: Provides long-term detection of drug use.

  • Hair Testing: Utilized for detecting drug intake over extended periods.

  • Adult PEth Testing: A biomarker test for estimating alcohol consumption.

  • Urine Testing: Employed for routine drug screening.


3. Substance Specialization
  • ChildGuard® Testing: Detects exposure to various cannabinoids like ∆8-THC, ∆9-THC, ∆10-THC, and CBD.

  • Xylazine Testing: Available in umbilical cord tissue.


4. Recent Innovations
  • SSRI Detection: In umbilical cord tissues to identify in-utero exposure.

  • Fentanyl Analyses: Expanded to hair, nail, meconium, and umbilical cord specimens.


Recent Developments



  • New Products and Features:

  • Xylazine Testing: Commenced as of September 5, in umbilical cord tissue.

  • SSRI Testing: Implemented for umbilical cord tissues to identify prenatal exposure to serotonin reuptake inhibitors.

  • Cannabinoid Additions: Enhanced ChildGuard® testing with ∆8-THC, ∆9-THC, ∆10-THC, and CBD detection.


  • Technological Shifts:

  • Transitioned various cannabinoid testing in hair and nails from GC-MS to the more advanced LC/MS/MS.


  • Research and Publications:

  • Recent studies published on umbilical cord tissue's efficacy in detecting substances such as ethanol, and involvement in various joint research endeavors.


  • Industry Impact:

  • Introduced innovative testing methods that are essential to various hospital operations, emphasizing neonatal health.


Partnerships and Collaborations



  • Active partnerships with agencies within the National Institutes of Health (NIH) to fund and promote breakthroughs in the field of analytical toxicology.

  • Collaboration with other researchers to advance biomarker assessments as objective methods of drug exposure evaluation.


These details provide a comprehensive overview of USDTL’s industry position, products, recent developments, and operational impact.